Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity

被引:0
|
作者
Lai, Jinzhi [1 ]
Huang, Rongfu [2 ]
Huang, Jingshan [3 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 2, Dept Oncol, Quanzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, Dept Clin Lab, Quanzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Quanzhou, Fujian, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
breast cancer; cancer stemness; radiosensitivity; PD-L1; tumor immune microenvironment; TUMOR MICROENVIRONMENT; IMMUNE CELLS; EXPRESSION; RADIOTHERAPY; RESISTANCE; RADIATION; CHEMOTHERAPY; FEATURES; THERAPY;
D O I
10.3389/fimmu.2025.1536284
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Understanding the role of cancer stemness in predicting breast cancer (BRCA) response to radiotherapy is crucial for optimizing treatment outcomes. This study developed a stemness-based signature to identify BRCA patients who are likely to benefit from radiotherapy.Methods Gene expression data for BRCA patients were obtained from the TCGA and METABRIC databases, including 920 TCGA-BRCA and 1980 METABRIC-BRCA patients. Univariate and multivariate Cox regression analyses were used to construct a radiosensitivity signature. Immune cell infiltration and pathway enrichment analyses were conducted using ESTIMATE and GSVA methods. The TIDE algorithm and the pRRophetic platform were employed to predict responses to radiotherapy. Radioresistant BRCA cells were examined using a colony formation assay. Key genes identified in the radiosensitivity signature were validated in vitro by qRT-PCR.Results By analyzing gene expression data from 920 BRCA samples, we identified a set of 267 stemness-related genes between high and low mRNAsi groups. Based on these genes, a radiosensitivity signature comprising two stemness-related genes (EMILIN1 and CYP4Z1) was constructed, stratifying patients into radiosensitive (RS) and radioresistant (RR) groups. Radiotherapy within the RS group significantly improved prognosis compared to non-radiotherapy patients. This signature was further validated in the METABRIC dataset. Notably, patients in the RS group also exhibited a significantly better response to immunotherapy compared to the RR group. We established a radioresistant BRCA cell line using the MCF-7 breast cancer cell line. A radioresistant breast cancer cell line (MCF-7/IR) was established by progressive exposure to increasing radiation doses. Comparative clonogenic and CCK8 assays demonstrated a radioresistant phenotype in the MCF-7/IR compared to MCF-7. In vitro studies utilizing both the MCF-7/IR and MCF-7 cell lines validated the expression of two radiosensitivity genes.Conclusion This study identified a stemness-related gene signature predictive of radiosensitivity in breast cancer. This signature may guide personalized treatment strategies and inform the development of novel radiosensitizing agents.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer
    Mi Jeong Kwon
    Archives of Pharmacal Research, 2019, 42 : 947 - 961
  • [42] Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines
    Hall, John S.
    Iype, Rohan
    Senra, Joana
    Taylor, Janet
    Armenoult, Lucile
    Oguejiofor, Kenneth
    Li, Yaoyong
    Stratford, Ian
    Stern, Peter L.
    O'Connor, Mark J.
    Miller, Crispin J.
    West, Catharine M. L.
    PLOS ONE, 2014, 9 (01):
  • [43] Construction and validation of stemness-related lncRNA pair signature for predicting prognosis in colorectal cancer
    Mya Thandar
    Yuanchang Zhu
    Xueying Zhang
    Zhifen Chen
    Yuena Zhao
    Shenghui Huang
    Pan Chi
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 11815 - 11828
  • [44] Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Haojun Shi
    Yiusing Tsang
    Yisi Yang
    BMC Cancer, 22
  • [45] Gene expression signatures: A tool for analysis of breast cancer prognosis and therapy
    Latha, Neetha Rajan
    Rajan, Arathi
    Nadhan, Revathy
    Achyutuni, Sarada
    Sengodan, Satheesh Kumar
    Hemalatha, Sreelatha Krishnakumar
    Varghese, Geetu Rose
    Thankappan, Ratheeshkumar
    Krishnan, Neethu
    Patra, Dipyaman
    Warrier, Arathy
    Srinivas, Priya
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 151
  • [46] A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
    Anne-Pierre Morel
    Christophe Ginestier
    Roxane M Pommier
    Olivier Cabaud
    Emmanuelle Ruiz
    Julien Wicinski
    Mojgan Devouassoux-Shisheboran
    Valérie Combaret
    Pascal Finetti
    Christelle Chassot
    Christiane Pinatel
    Frédérique Fauvet
    Pierre Saintigny
    Emilie Thomas
    Caroline Moyret-Lalle
    Joël Lachuer
    Emmanuelle Despras
    Jean-Luc Jauffret
    François Bertucci
    Jérôme Guitton
    Anne Wierinckx
    Qing Wang
    Nina Radosevic-Robin
    Frédérique Penault-Llorca
    David G Cox
    Frédéric Hollande
    Stéphane Ansieau
    Julie Caramel
    Daniel Birnbaum
    Arnaud M Vigneron
    Agnès Tissier
    Emmanuelle Charafe-Jauffret
    Alain Puisieux
    Nature Medicine, 2017, 23 : 568 - 578
  • [47] Establishment of a circular RNA regulatory stemness-related gene pair signature for predicting prognosis and therapeutic response in colorectal cancer
    Chen, Qian
    Tang, Peng
    Huang, Huishen
    Qiu, Xiaoqiang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Construction and validation of stemness-related lncRNA pair signature for predicting prognosis in colorectal cancer
    Thandar, Mya
    Zhu, Yuanchang
    Zhang, Xueying
    Chen, Zhifen
    Zhao, Yuena
    Huang, Shenghui
    Chi, Pan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 11815 - 11828
  • [49] Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
    Shi, Haojun
    Tsang, Yiusing
    Yang, Yisi
    BMC CANCER, 2022, 22 (01)
  • [50] Gene signatures in the breast cancer
    Bernet, Laia
    Fernandez, Pablo
    Hardisson, David
    Chic, Nuria
    Pascual, Tomas
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2022, 35 : S67 - S86